Wasnt that just prior to the asset transfer with Opko, and the subsequent $16m placement ti Frost et.al. ? Or am I mistaken?
As for an offering, I agree with hanna. Just as likely future $ may follow partnering, just a guess.
good luck All
btw, I am convinced that those who have the ability, have manipulated RXI's pps for just the reasons that etsch mentioned. The daily regularity of both % and volume is very telling of same.
As for the anticipation of any interin p2 news, mid year is the expectation per the company. GLTA
Golong, what is the basis for your determination of "at least" 45% reduction or better for a successful trial? Seems an arbitrary number to me. Scarring is an unmet need of great proportion.
How do you arrive at that conclusion? thanks.
Apparently from your robo postings, I,ve upset you hedge. You see you are no match hedge, you are an hourly paid lackey. We all know that. it doesn't make you bad. We all have to work for a living,
Its just that ( and don't take this personal) nobody likes what you do for a living.
Working fr the hedge fund bosses is your game hedge. Personally, I think you have the ability to rise above that... I do see some positive qualities in you.................
Perhaps you can enroll for the trials the the monkies avimoron. All the bananas you can eat. You'll fit right in, HAHAHA
Are enrolling themselves in the monkey experiments? All the bananas you can eat fellas.........
In full agreement. judge the regularity of both the daily drops and volume. Manipulation no doubt. Now watch for them to do just the opposite, can create unsustainable higher pps. Similar to fast spike we had last year. Watch closely.
Just my thought this morning. good luck All
Hello orchid, p2a scar revision alone will take us beyond that level. Interim report due mid year, per the company. On the positive side, just as the scar trials are greatly expedited to to the fact that results are fast due to nature of skin healing, and results are visible.
So will be the nature of trials involving the eye, quick healing and visible.
Nice to see green for a change.......good luck All
And in charge of RXI's opthalmology development. Sr. devlp director of Sirna from 2002-2006 when Sirna was purchased by Merck for $1.1B.
She also managed Sirna's partnership with Allergan, A company who I feel will be very interested in today's news. It is right up their alley.
Big pharma is on the hunt to add to their pipelines. They are buying rather than developing in house. Just look at all the Pharma deals past few weeks. Just today Astra Zeneca turned down a $106.5 billion (yes you read that correctly) from Pfizer.
Dr. Cauwenbergh keeps putting one foot before the other, A master of creating value.....good luck All
exactly. Cawenbergh was not born yesterday, he's going with a proven commodity, rx1-109 and all its potential applications. The very reason why he included keloid revision in p2. good luck All
exactly lotta, Wall Street's finest. And the SEC ( the outfit that could not pinpoint Bernie Madoff after they were told 100 times that he was a Ponzi sheme) did nothing.
Market makers are allowed to trade the very same stocks that they make market for. now you tell me....
Quote Dr. Cauwenbergh; "This finding opens up an avenue to possibly develop topical forms of RXI-109 to combat corneal scarring which often occurs secondary to trauma or infection and can lead to visual impairment including blindness"
Enter Phosphagenics, An Aussie company specializing in delivering compounds "to and through" the skin. And to which just last month Dr. C. was appointed to their board. Interesting?
Novartis is among the companies currently utilizing Phosphagenics' technology.
He keeps placing one foot in front of the other...........good luck All
Many thanks for the post autumn. Hopefully pressure may be mounting for the need to deal with deconverting 700,000 ton of UF6. 700,000 ton? I think that weighs more than my town.........good luck all
How are Retinal Detachments treated?
Retinal detachment can occur at any age and is accompanied by partial loss of the field of vision. This may progress to almost total loss of vision. Retinal detachments are repaired using a variety of surgical techniques that are successful in more than 90 percent of all cases. Most patients require only one operation to successfully repair a detached retina.
What is Proliferative Vitreoretinopathy?
Normal healing can sometimes be complicated by the development of scar tissue, a process known as proliferative vitreoretinopathy (PVR). This scar tissue develops in the vitreous cavity that stiffens the retina and results in the re-detachment of the retina. This recurrent retinal detachment will require a vitrectomy operation using specialized techniques. Careful removal of all scar tissue on or under the retina is required. The retina is reattached using a gas bubble or silicone oil. Your physician will discuss your special needs prior to surgery.
Can vision be saved?
Since PVR with stiffening of the retina is a complicated process, the chance of successful surgery is lessened. With modern techniques, however, some vision can still be saved. Following surgery, you may need to keep your head elevated or in a special position to assist in the re-attachment. Eye drops and other medications will be prescribed on an individual basis. If the retina is surgically re-attached, the vision should begin to return in several months, but any return of vision with PVR should be considered a success.